|
 The new drug, Savaysa, will compete with older blood thinners,
including Xarelto, sold by Bayer AG and Johnson & Johnson,
Boehringer Ingelheim's Pradaxa, and Bristol-Myers Squibb Co's
Eliquis.
The Food and Drug Administration said the Daiichi drug is also
approved to treat deep vein thrombosis and pulmonary embolism in
patients who have already been treated with an anti-clotting drug
administered by injection or infusion, for five to ten days.
The agency said that, as with other approved anti-clotting drugs,
bleeding, including life-threatening bleeding, is the most serious
risk with Savaysa.
Atrial fibrillation affects about 3 million Americans, causing blood
to pool in a storage chamber of the heart, where it can clot and
travel to the brain.
(Reporting By Deena Beasley. Editing by Andre Grenon)
[© 2014 Thomson Reuters. All rights
reserved.] Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
[to top of second column] |
|
